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A B S T R A C TObjectives: In 2012, the National Institute for Health and Care
Excellence assessed dasatinib, nilotinib, and standard-dose imatinib
as ﬁrst-line treatment of chronic phase chronic myelogenous leu-
kemia (CML). Licensing of these alternative treatments was based on
randomized controlled trials assessing complete cytogenetic
response (CCyR) and major molecular response (MMR) at 12 months
as primary end points. We use this case study to illustrate the
validation of CCyR and MMR as surrogate outcomes for overall
survival in CML and how this evidence was used to inform National
Institute for Health and Care Excellence’s recommendation on the
public funding of these ﬁrst-line treatments for CML. Methods: We
undertook a systematic review and meta-analysis to quantify the
association between CCyR and MMR at 12 months and overall
survival in patients with chronic phase CML. We estimated life
expectancy by extrapolating long-term survival from the weighted
overall survival stratiﬁed according to the achievement of CCyR
and MMR. Results: Five studies provided data on the observational
association between CCyR or MMR and overall survival. Based on thesee front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.07.004
ani@pcmd.ac.uk.
ondence to: Ciani Oriana, PenTAG, Institute for Hea
ol Lane, EX2 4SG Exeter, UK.pooled association between CCyR and MMR and overall survival, our
modeling showed comparable predicted mean duration of survival
(21–23 years) following ﬁrst-line treatment with imatinib, dasatinib,
or nilotinib. Conclusions: This case study illustrates the consid-
eration of surrogate outcome evidence in health technology
assessment. Although it is often recommended that the accept-
ance of surrogate outcomes be based on randomized controlled
trial data demonstrating an association between the treatment
effect on both the surrogate outcome and the ﬁnal outcome, this
case study shows that policymakers may be willing to accept a
lower level of evidence (i.e., observational association).
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Chronic myeloid leukemia (CML) is a myeloproliferative neo-
plasm of hematopoietic stem cells [1]. CML used to be regarded
as a progressive disease whose natural history evolves through
three phases: the initial chronic phase, during which the disease
is stable or at the most only slowly progressive, followed after a
variable interval by transition through an accelerated phase to a
rapidly fatal blast crisis [2–4]. Approximately 90% of the people
affected by CML are diagnosed during the chronic phase, with a
median age at diagnosis of around 65 years [2]. In the United
States, about 4800 to 5200 new cases are diagnosed every year,
which corresponds to an annual incidence of 1.0 to 1.3 per
100,000 population [5,6]. Similar annual age-standardizedincidence rates have been published for the United Kingdom
(i.e., 1.1 per 100,000 for men and 0.7 per 100,000 for women) [7].
Before the introduction of tyrosine kinase inhibitor (TKI) therapy,
the median survival time after diagnosis was 6 years [6], with a
predicted 5-year overall survival of 42.7% [8] and estimated
prevalence of 25,000 to 30,000 cases in the United States [6] and
of 4,000 to 5,000 cases in the United Kingdom [9].
The molecular pathogenesis of CML is well understood, and the
disease presents the Philadelphia chromosome (Ph) as a molecular
hallmark [10]. This fusion gene is the result of a reciprocal
chromosomal translocation (i.e., t [9;22]), also known as breakpoint
cluster region-Abelson (BCR-ABL) oncogene, that codes for BCR-ABL
transcripts and fusion proteins with unusual tyrosine-kinase
activity [11,12]. Diagnosis is conﬁrmed by the identiﬁcation ofociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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bone marrow cells, through cytogenetic [11–14] analysis or reverse
transcriptase polymerase chain reaction (PCR), which can be semi-
quantitative (real-time PCR or quantitative PCR) [15]. Following
recognition of the importance of achieving a certain depth of
response at different time points for patients with newly diagnosed
CML in chronic phase, the European LeukemiaNet has established
guidelines on therapeutic milestones that should be achieved [15].
A complete cytogenetic response (CCyR) is deﬁned as absence of
the Ph among at least 20 cells in metaphase in a bone marrow
aspirate [16], while a major molecular response (MMR) is reached if
the standardized BCR-ABL:ABL ratio is less than 0.1%, which is
equivalent to a 3 log reduction from the 100% baseline for
untreated patients [17,18].
Knowledge of the molecular basis of this neoplastic disease
has led to a new generation of drugs, the TKIs, radically changing
the previous standard of care based on interferon-alpha (IFN-α)
for patients with CML [13,14]. Imatinib, the ﬁrst rationally devel-
oped selective TKI to be approved for the treatment of a cancer
[19] by the European Medicines Agency in 2001, was rapidly
adopted as ﬁrst-line medical treatment for CML in chronic phase
in the National Health Service in the United Kingdom [20]. The
efﬁcacy of imatinib in comparison with older treatments has
been conﬁrmed in a single randomized controlled trial (RCT), the
International Randomized Study of Interferon and STI571 (IRIS)
trial [14], a prospective, multicenter, open-label, phase 3 RCT
comparing imatinib 400 mg/day with IFN-α plus cytarabine. In
early 2012, two newer TKIs—dasatinib [17,21] and nilotinib [22–
24]—initially promoted for the treatment of patients resistant or
intolerant to imatinib [15,25], have been assessed by the National
Institute for Health and Care Excellence (NICE) as alternative ﬁrst-
line treatments to imatinib in England and Wales [26]. The
evidence of the relative effectiveness of these three alternative
treatment options was based on two comparative RCTs, one that
compared dasatinib with imatinib [21] (Dasatinib vs. Imatinib in
Patients With Newly Diagnosed Chronic Phase CML, the DASI-
SION trial) and the other comparing nilotinib with imatinib [24]
(Evaluating Nilotinib Efﬁcacy and Safety in clinical Trials-newly
diagnosed patients, the ENESTnd trial). In both trials, the primary
end points were biomarkers, that is, conﬁrmed CCyR by 12
months in DASISION and MMR at 12 months in ENESTnd.
Although average survival from diagnosis can reach 15 years
[25] among this population, these two trials provide only imma-
ture data on overall survival with a maximum follow-up of 2
years at the time of the assessment.
Central to this coverage decision, therefore, was consideration
of CCyR and MMR as valid surrogate outcomes (i.e., biomarkers
intended to substitute and predict for a ﬁnal patient-relevant
outcome [27]) for long-term overall survival in ﬁrst-line TKI
therapy for chronic phase CML to determine estimates of life-
years gained across alternative treatments [28].
The dual aims of this study were 1) to assess the evidence
base for the use of CCyR and MMR as surrogates for overall
survival in patients with chronic phase CML treated with TKI (i.e.,
dasatinib, nilotinib, and imatinib) and 2) to describe how this
evidence was used to predict long-term survival in the related
cost-effectiveness model. The policy implications of the valida-
tion and use of surrogate outcomes in coverage decisions will be
discussed.Methods
This study consisted of two distinct methodological steps: 2) a
systematic review and meta-analysis of the evidence base to
quantify the association between CCyR and MMR as surrogates
for overall survival in chronic phase patients with CML treatedwith ﬁrst-line TKIs and 2) modeling of the observed CCyR and
MMR at 12 months to predict long term (412 months) patient
survival in ﬁrst- and second-generation TKI therapies.
Systematic Review and Meta-Analysis
Our systematic review and meta-analysis was conducted and
reported in accord with the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses statement [29].
Search strategy
We initially identiﬁed studies from a previous systematic review
of imatinib for ﬁrst-line treatment of CML in chronic phase [30].
The following bibliographic databases were searched: Medline,
Medline in Process, Embase, PsycINFO (all via OVID), The
Cochrane Library, Web of Science (via ISI), and Econlit (via CSA)
from October 2002 (the end date of the previous systematic
review [30]) to May 2012. The searches were limited to the English
language. The Medline search strategy is reported in the Supple-
mental Material found at http://dx.doi.org/10.1016/j.jval.2013.07.
004.
Inclusion criteria
Studies were included if they considered 1) adults (median age4
18 years) with chronic phase CML based on cytogenetic and/or
ﬂuorescence in situ hybridization and/or reverse transcriptase
polymerase chain reaction results; 2) patients treated with
dasatinib, nilotinib, or imatinib; 3) patients naive to previous
interferon or TKI treatment; and if they 4) reported the associa-
tion between CCyR or MMR at 12 months and overall survival. We
excluded studies published only as conference abstracts, narra-
tive reviews, editorials, opinion pieces, and individual case
studies, or studies whose ﬁndings were not judged to be general-
izable to the CML population in the United Kingdom or Western
countries. Where a study had been reported in several publica-
tions, we considered the article with the longest follow-up. Titles,
abstracts, and full text of any potentially relevant studies were
independently screened by two reviewers (O.C. and T.P.) with any
discrepancies resolved by discussion, with the involvement of a
third reviewer if necessary.
Data extraction and quality assessment
The methodological quality of included studies was assessed
according to a modiﬁed list of criteria speciﬁed by the National
Health Service Centre of Reviews and Dissemination [31]. Study
characteristics and data were extracted by one reviewer (O.C.) by
using a standardized data extraction form and independently
checked by a second reviewer (T.P. or R.T.). To judge the reliability
of CCyR and MMR at 12 months as surrogate measures for long-
term overall survival, we referred to the following surrogate
validation criteria: 1) evidence from RCTs demonstrating treat-
ment effects on the surrogate correspond to treatment effects on
the patient-relevant outcome, 2) evidence from observational
studies demonstrating consistent association between surrogate
outcome and ﬁnal patient-relevant outcome, and 3) evidence of
biological plausibility of relationship between the surrogate out-
come and the ﬁnal patient-relevant outcome [32].
Data analyses
For each study, overall survival was extracted at each year
following trial recruitment (or randomization) up to the latest
follow-up point reported, separately according to whether a CCyR
or an MMR was achieved at 12 months. In all studies, overall
survival data were estimated by the Kaplan-Meier method by using
landmark analysis to evaluate differences in the ﬁnal patient-
relevant outcomes between responders and nonresponders.
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ﬁxed time point, with survival calculated from that time point
onward and associated statistical tests being conditional on
patients’ landmark responses [33]. Data digitalization software
(WinDIG Version 2.5) was used to extract data from Kaplan-Meier
survival curves.
For consistency, we selected 12 months after the start of ﬁrst-
line therapy as the landmark for our analysis, as the DASISION
[21] and ENESTnd [24] trials consider, respectively, the rate of
conﬁrmed CCyR and MMR at 12 months postrandomization as
primary end points. Average overall survival rates at yearly
intervals were estimated for both responders and nonresponders,
weighted by the initial number of patients in the two groups for
each trial. Wilson 95% conﬁdence intervals (CIs) were derived for
each point estimate assuming binomial distributed variables and
no censoring of data [34]. Analyses were undertaken by using
STATA v.11.2 (StataCorp, TX).
Modeling and Data Extrapolation
The above systematic review and meta-analysis provided a
literature-based estimation of overall survival, according to
whether patients with CML achieved either a CCyR and MMR
response or not. A four-step analytical approach was then under-
taken to estimate long-term overall survival separately for
imatinib, dasatinib, and nilotinib treatment.– Step 1: CCyR and MMR response rates at 12 months for
dasatinib from ENESTnd [24] and for nilotinib from DASISION
[21] were derived by using a WinBUGS mixed-treatment
comparison analysis [35,36]. The appropriateness of the indi-
rect comparison was assessed by checking that the baseline
characteristics of the two trials were similar. A ﬁxed-effects
pairwise meta-analysis [37] was then undertaken to obtain an
overall estimate of the proportion of patients achieving a
CCyR and separately an MMR for each treatment [38].– Step 2: Estimation of CML-related mortality from historical
trial data [38]. Mortality was assumed to occur because of
CML-related causes and non-CML causes. Given limited and
immature historical data on CML-related death, the proba-
bility of CML-related death was assumed constant over time
(as this was deemed most parsimonious), and to depend on
whether a CCyR was achieved. In a separate exercise, the
probability of CML-related death was assumed to depend on
whether an MMR was achieved. Non-CML mortality was taken
from UK life tables [39], and the age at diagnosis was
estimated as the average age at diagnosis across all historical
trials, weighted by the number of responders or nonrespond-
ers in each trial, as appropriate. The constant probability of
CML-related death was estimated to minimize the sum of
squares of differences between the actual historical overall
survival and modeled overall survival at each year.– Step 3: Estimation of overall survival separately for responders
and nonresponders given a cohort of patients starting ﬁrst-
line treatment at age 57 years (i.e., the mean age at diagnosis
in the United Kingdom) [7]. Overall survival was estimated by
applying mortality from the general population with starting
age 57 years and the appropriate estimate of CML-related
mortality from step 2.– Step 4: Estimation of overall survival for each treatment arm
(i.e., imatinib, dasatinib, and nilotinib) by averaging the
responder and nonresponder overall survival, estimated in
step 3, weighted by the proportion of patients who did and did
not achieve a response to ﬁrst-line treatment at 12 months.
We compared our estimates of expected overall survival with the
actual 24- and 36-month overall survival from the ENESTnd trial[40,41], the 24-month overall survival from the DASISION trial
[42], and the longer term (i.e., 7 years) imatinib survival data from
the IRIS trial [43]. In addition, two sensitivity analyses were
performed on the pool of articles that contributed historical data
by 1) excluding IRIS trial reports [43,44] and 2) including the
unique dasatinib- and nilotinib-treated patient cohort identiﬁed
in the Jabbour et al. study [45]. Given that the IRIS trial has been
used for validation, the former was performed to test the
inﬂuence of IRIS data on the estimated surrogate relationship,
while the latter was performed to check whether the same
relationship might be speciﬁc to type of TKIs.
Modeling analyses were carried out by using WinBUGS (MRC
Biostatistics Unit, Cambridge, UK) and the Excel “Solver” function
(Excel 2012 Microsoft Corporation, Redmond, WA).Results
Study Identiﬁcation
The process of study selection is summarized in Figure 1. Six
publications met the inclusion criteria, reporting on ﬁve separate
studies—two RCTs and three cohort studies (Table 1).
Study and population characteristics
We were able to include ﬁve studies in the quantitative analysis.
One study, performed in India, was judged to be unlikely to
reﬂect the clinical management of patients with CML in devel-
oped economies and therefore excluded [49]. Only one arm in a
cohort study reported patients with CML who were treated by
dasatinib or nilotinib [45], with all the others considering imatinib
treatment. We therefore decided to include only the imatinib
treatment arm from the same study in our base-case analysis
and to contrast the overall results with those reported for the
dasatinib and nilotinib arm in Jabbour et al. [45]. As for the two
RCTs, only the arms receiving standard-dose imatinib as ﬁrst-line
therapy were considered. This choice was taken because 1) the
IRIS trial was inadequate to demonstrate a survival beneﬁt for
imatinib relative to IFN-α therapy in newly diagnosed Phþ
chronic-phase CML in the light of the high rate of crossover
(65% at 72-month follow-up) from IFN-α plus cytarabine to
imatinib [50], and 2) Hehlmann et al. [48] compared the 400 mg/
day imatinib with the high-dose therapy (i.e., 800 mg/day) or
combined therapy with interferon, which were not among the
treatment options under comparison in our analysis.
Study quality and hierarchy of surrogate evidence
The included studies consistently showed moderate to good
internal validity (see Table 1 in Supplemental Material found at
http://dx.doi.org/10.1016/j.jval.2013.07.004) and were therefore all
considered in the base-case analysis. In the two RCTs [43,44,48],
the association between CCyR and MMR and overall survival was
examined as a stratiﬁed comparison of overall survival in MMR
and CCyR responders versus nonresponders for the imatinib 400
mg/day arm only. Thus, the level of surrogate outcome evidence
identiﬁed by this review was entirely observational, that is,
“level 2” evidence according to the three-level surrogacy evalua
tion scheme proposed by Elston and Taylor [32].
Association between CCyR or MMR at 12 months and overall
survival
Table 2 shows the weighted pooled mean overall survival (and 95%
CI) at yearly intervals, up to 7 years after the initiation of imatinib
treatment, according to achievement of CCyR and MMR (or not) at 12
months [43–48]. For imatinib-treated patients with CML, the impact
of achieving a CCyR at 12 months progressively translate into a
Fig. 1 – Flow diagram of the study inclusion process.
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response. The advantage of achieving an MMR at 12 months in
terms of overall survival rates, however, is less clear. Overall survival
rate estimates for imatinib-treated patients are slightly lower than
the level of overall survival seen in the cohort of patients treated
with nilotinib or dasatinib who achieve a CCyR at 12 months after
treatment initiation in Jabbour et al. [45], although without reaching
statistical signiﬁcance (logrank test: P ¼ 0.80).Prediction of long-term overall survival
The estimated long-term overall survival for responders and
nonresponders compared with our literature-based synthesized
historical data and survival for the general population in England
and Wales is shown in Figure 2. After considering CCyR and
MMR response rates by 12 months for each of the three treatment
arms under comparison (see Table 2 in Supplemental Material
found at http://dx.doi.org/10.1016/j.jval.2013.07.004), we were able
to stratify long-term extrapolated overall survival by therapy
(Fig. 3).
The extrapolated long-term overall survival curves for ima-
tinib, dasatinib, and nilotinib treatment appear very compara-
ble. The estimated mean overall survival across the three
therapies (see Table 3 in Supplemental Material found at
http://dx.doi.org/10.1016/j.jval.2013.07.004) ranges from 2.7 to
4.1 years less than the life expectancy of the general population
of England and Wales. Taking into account the potential
uncertainties in the estimation of trial-based response rates,
according to our model, people treated with ﬁrst-line imatinib
are expected to survive 21.3 years on average, 1.4 years less
than people treated with nilotinib and dasatinib, using the
CCyR data. They are expected to survive 22.0 years, 0.6 years
less than patients treated with dasatinib and nilotinib, when
using the MMR data. Results from the sensitivity analyses
showed little or no impact on estimated mean overall survival
when data from the IRIS trial were excluded [43,44] or when
data from the dasatinib and nilotinib cohort [45] were included,
thus supporting the consistency of the surrogate to ﬁnal out
come relationship across the interventions.We checked the accuracy of our estimates by comparing mod-
eled overall survival and trial-based overall survival from the two
RCTs of ﬁrst-line dasatinib [21] and nilotinib [24] and from the
imatinib arm of the IRIS trial [43]. It appears that themodeled overall
survival is consistent with these data:– at 2-year follow-up, dasatinib overall survival observed in
DASISION was 95% compared with 97% estimated by our
model [42];– at 2-year follow-up, nilotinib overall survival observed in
ENESTnd was 97% [40] compared with 97% in the model; at
3-year follow-up, the overall survival observed in the trial was
95% [41] compared with 95% estimated by the model;– imatinib observed overall survival was 95% and 96% in
DASISION and ENESTnd, respectively, compared with 96% in
the model based on the CCyR surrogate relationship and 97%
based on the MMR surrogate relationship [40,42].
In addition, the estimated overall survival for the imatinib arm
closely predicts the actual overall survival in the imatinib arm of
the IRIS RCT (see Fig. 1 in Supplemental Material found at http://
dx.doi.org/10.1016/j.jval.2013.07.004). This is not a completely
independent veriﬁcation of overall survival through this method,
because some of the data on overall survival for imatinib
responders and nonresponders from the IRIS RCT were also used
to estimate the overall survival surrogate relationships. Nonethe
less, it serves as useful calibration of the model’s survival outputs
because other historical data also heavily inﬂuenced the surro-
gate overall survival estimates.Discussion
The molecular biology of CML supports the adoption of both CCyR
and MMR as potential markers for monitoring of disease pro-
gression [13,51]. It has also been shown, however, that TKIs can
have potential unexpected off-target effects (i.e., stem cells
chromosomal instability, inhibition of proinﬂammatory func-
tions [52–55]) that may call into question the ability of these
Table 1 – General characteristics of studies used to estimate surrogate relationships between response and survival.
de Lavallade
et al. [46]
Kantarjian et al.
[47]
Jabbour et al.
[45]
Hehlmann et
al. [48]
Hughes et al. [43]
(IRIS)
Roy et al.
[44] (IRIS)
Country UK US US US Germany International International
Year published 2008 2008 2011 2011 2011 2010 2006
Study type Cohort Cohort Cohort Cohort RCT RCT RCT (retrospective
comparison)
N patients
(TKI arm)
204 276 73 154 324 476 551
Median age (y)
(range)
46 (18–79) 48 (15–84) 48 (15–78) 47 (18–85) 54 (16–88) 50 (20–69) 50 (18–70)
Intervention Imatinib
400 mg/d
Imatinib
400 mg/d or
800 mg/d
Imatinib
400 mg/d
Dasatinib or
nilotinib
Imatinib
400 mg/d
Imatinib
400 mg/d
Imatinib 400
mg/d
Comparator None None None None Imatinib
400 mg/d
combined with
IFN Imatinib
800 mg/d
IFN-α plus
cytarabine
IFN-α plus
cytarabine
Median follow-up
(mo)
38 48 110 28 43 77 42
Comparison
between
responders vs.
nonresponders
CCyR vs. no CCyR CCyR vs.
minor CyR†
MMR vs. no MMR
CCyR vs. no
CCyR
CCyR vs. no
CCyR
MMR vs. no
MMR
MMR vs. no
MMR
CCyR vs. no
CCyR
Male sex, n (%) 116 (57) NA NA NA 194 (60) 296 (62) 341 (62)
Median time
from diagnosis
to treatment (mo)
1.7 1.1 1 1 0.6 (within 6 mo
before study
entry)
(within 6 mo
before study
entry)
Sokal risk
score‡, n (%)
Low: 59 (29) Low: 179 (65) Low: 50 (68) Low: 118 (77) EuroSCORE Low: 175 (37) Low: 201 (37)
Low: 113 (35) Intermediate: 99
(21)
Intermediate: 111
(20)
Intermediate: 86
(42)
Intermediate: 76
(27)
Intermediate:
22 (30)
Intermediate: 27
(18)
Intermediate: 172
(53)
High: 63 (13) High: 71 (13)
High: 59 (29) High: 21 (8) High: 1 (2) High: 9 (5) High: 39 (12) Not known: 139
(29)
Not known: 168
(30)
Population Phþ CML in CP Phþ CML in CP CML in CP§ CML in CP§ CML in CP Phþ CML in CP Phþ CML in CP
CcyR, complete cytogenetic response, CP, chronic phase; EuroSCORE, European System for Cardiac Operative Risk Evaluation; IFN-α, interferon-alpha; IRIS, International Randomized Study of
Interferon and STI571; MMR, major molecular response; Phþ, Philadelphia chromosome positive; RCT, randomized controlled trial; TKI, tyrosine kinase inhibitor.
 Jabbour et al. [45] studied three cohorts of patients treated, respectively, with imatinib 400 mg daily, imatinib 800 mg daily, and second-generation TKIs (i.e., nilotinib and dasatinib). We excluded
the imatinib 800 mg daily arm for the purpose of this analysis as nonlicensed dose. Data from imatinib 400 mg daily cohort were included in our base-case analysis; data from the second-
generation TKIs cohort were used in a sensitivity analysis.
† The group of people achieving a minor cytogenetic response at 12 mo after the ﬁrst-line treatment initiation (N ¼ 5) in Kantarjian et al. [47] study report was excluded from the pooled overall
survival average estimate.
‡ Sokal score is a prognostic classiﬁcation system for patients with chronic myeloid leukemia that is designed to identify patients with low, intermediate, or high risk of poor outcome.
§ More than 85% of the patients are Phþ.
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Table 2 – Pooled weighted mean overall survival (and 95% CI) by CCyR and MMR response (or not) at 12 mo after
the starting of imatinib therapy.
Time (mo) OS % (95% CI)
CCyR No CCyR P† MMR No MMR P†
12 100 (99.4– 100) 100 (98.1–100) 1.00 100 (99.1– 100) 100 (99.4– 100) 1.00
24 98.3 (96.8– 100) 94 (89.7–96.5) 0.15 100 (99.1– 100) 96.7 (95.0– 97.9) 0.42
36 97.7 (96.2–98.6) 88.9 (83.9– 92.2) 0.03 99.2 (98.0– 99.8) 95.7 (93.8– 97.1) 0.35
48 98.3 (96.1– 99.4) No data Not calculable 96.6 (94.4– 97.9) 93.3 (91.0– 95.0) 0.20
60 97.4 (95.2– 98.6) 73.6 (62.4– 82.4) 0.02 96.9 (95.1– 98.1) 89.4 (86.9– 91.5) 0.11
72 98 (88.4–99.6) No data Not calculable 96.0 (93.2– 97.5) 90 (87.0– 92.3) o0.01
84 94 (82.1– 97.7) No data Not calculable 92.5 (87.6– 95.9) 89.2 (83.5– 93.4) NS
CcyR, complete cytogenetic response; CI, conﬁdence interval; MMR, major molecular response; NS, nonsigniﬁcant; OS, overall survival.
 Wilson 95% CIs.
† P value for difference in the OS rate between responders and nonresponders. Where more than one studies are available, P values derived
from t-statistic meta-regression analysis. Where only one study is available, P values derived from the study publication.
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TKI therapy. In this article, we assessed the empirical evidence
for the use of CCyR and MMR at 12 months as surrogate outcomes
for overall survival in patients with chronic phase CML receiving
ﬁrst-line TKI treatment.
The results conﬁrm the current adoption of CCyR at 12
months as a gold standard for a good response, whereas MMR
provides a measure of success rather than a measure of failure
(i.e., not achieving high levels of molecular response does not
constitute treatment failure in patients with CML) [25]. Our
systematic review identiﬁed three cohort studies [45–47] and
two RCTs [43,44,48] examining the association between these
two biomarkers and overall survival in patients with chronic
phase CML receiving ﬁrst-line imatinib. While these studies
showed a consistent association between CCyR and MMR and
long-term (i.e., 1–7 years) overall survival, this was based on
observational analyses comparing responders versus nonrespond-
ers. Based on the pooled observational association between CCyR
and MMR and overall survival, our modeling showed comparable
predicted mean duration of survival (21–23 years) following ﬁrst-
line treatment with imatinib, dasatinib, or nilotinib.
Although a plausible biological rationale constitutes a basic
step toward the identiﬁcation of a surrogate outcome [32,56,57], it
is not sufﬁcient by itself to prove that the treatment effect on the
substitute end point may predict the treatment effect on the ﬁnal
patient-relevant outcome. Empirical evidence of an association
between these end points and ﬁnal patient-relevant outcome, as
well as between treatment effects on them is also needed. Ideally,
this evidence should be in the form of multiple RCTs that assess
the effects of the treatment on both the end point marker and
ﬁnal patient-relevant outcome at relevant follow-up time [58].
Findings of Previous Studies
To our knowledge, this is the ﬁrst systematic review and meta-
analysis to examine the scientiﬁc basis of the validation of CCyR
and MMR as surrogates for long-term overall survival in patients
with chronic phase CML treated with TKIs. Two previous studies
have examined this question in patients treated with IFN-α.
Anstrom et al. [59] ﬁtted a proportional hazards model to
estimate long-term survival by conditioning on CCyR at 2 years
landmark time point. Their data sources were the IRIS trial at 19-
month follow-up [14] and four clinical trials [60–63] assessing
patients treated with IFN-α plus low-dose cytarabine. They
predicted a residual life expectancy after CCyR at 2 years of 16.7
years and of 5.8 years for non-CCyR cohorts. In comparison, our
estimates were 24.5 and 14.3 years, respectively. The lifeexpectancy estimates of Anstrom et al. [59] for ﬁrst-line imatinib
were 15.3 years compared with our estimate of 21.3 years using
CCyR as a surrogate. The differences in the estimates can be
explained ﬁrst by the different landmark time considered for the
CCyR (i.e., 1 year vs. 2 years), second by the choice of the baseline
survival functions (i.e., life-table estimates for the general U.S.
population weighted according to baseline age and sex distribu-
tions of the IRIS population vs. UK life-table estimates weighted
by the number of responders or nonresponders in each trial, as
appropriate), and third by the assumption that long-term survival
estimates for imatinib-treated patients are similar to those
derived from two cohorts of IFN-α–based regimens with [61] or
without [60] CCyR at 2 years.
Schrover et al. [64] assumed that prolonged survival after
attaining a major cytogenetic response (i.e., 0%–35% Phþ cells
among at least 20 cells in metaphase in a bone marrow aspirate)
may be independent of treatment and developed a survival model
for patients with chronic phase CML using a logistic regression to
predict survival according to major cytogenetic response rate. They
estimated an average difference in survival between responders
and nonresponders at 2 and 4 years after landmark of 15.0% and
25.8%, respectively, and predicted a proportion of patients alive at 5
year of 70%. Our model predicts more favorable outcomes for the
patients (i.e., ﬁtted 5-year survival in patients without CCyR is 77%,
98% in patients with CCyR); however, our results cannot be easily
compared with those reported by Schrover et al. [64], given that
they considered a different surrogate end point and data derived
from IFN-α– based RCTs.
Recently, a systematic review and meta-analysis has evaluated
the efﬁcacy and safety of second-generation TKIs (including bosu-
tinib) versus imatinib [65]. The inclusion criteria for this study were
slightly different from those in our systematic review: Gurion et al.
[65] considered only RCTs, also published as conference abstracts,
with no restriction on adult population. Although the objective was
not that of validating CCyR and MMR at 12 months as surrogates
for overall survival, they observed no statistically signiﬁcant differ-
ence between ﬁrst- and second-generation TKIs groups in all-cause
mortality rates at 12 months (relative risk [RR] 0.76; 95% CI 0.42–
1.37) despite a general improvement in the CCyR rate at 12 months
(RR 1.16; 95% CI 1.09–1.23) and MMR at 12 months (RR 1.68; 95% CI
1.48–1.91) in patients allocated to the second-generation TKIs arm
as compared to patients allocated to the imatinib arm.
Strengths and Limitations
In a situation in which only evidence about clinical effectiveness
measured in terms of cytogenetic or molecular response and
Fig. 2 – Observed vs. ﬁtted overall survival for patients (a) with and without a CCyR (upper panel) and (b) with and without a
MMR (lower panel) at 12 months. CCyR, complete cytogenetic response at 12 months; MMR, major molecular response at 12
months. Observed overall survival rates derived from Table 2.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 0 8 1 – 1 0 9 0 1087immature data about overall survival were available, we systema-
tically looked for evidence supporting the adoption of both CCyR
and MMR at 12 months as reliable predictors of overall survival by
looking at TKIs-treated patients data, naive to previous pharma-
cological therapies for CML. In fact, although initial marketing-
authorization for imatinib was granted on the primary efﬁcacy
end point of the proportion of patients achieving major cytoge-
netic response, based on the strong association between cytoge-
netic response and survival observed with IFN-α, the
accompanied scientiﬁc discussion document speciﬁed that themechanisms of action of imatinib and IFN-α were different and
the association between survival improvement and achievement
of cytogenetic response needed to be conﬁrmed for imatinib and
following TKI drugs [66].
Nonetheless, we acknowledge some potential limitations in our
analysis. First, we were able to examine the validity of the two
biomarkers as surrogate end points only on the basis of aggregate
data. Access to individual patient data has the advantage of stand-
ardizing the methods of statistical analysis not only across but also
within studies [67]. Second, we relied on a landmark analysis, which
Fig. 3 – Overall survival for each treatment arm estimated by surrogate relationship based on CCyR and MMR separately. CCyR,
complete cytogenetic response at 12 months; MMR, major molecular response at 12 months.
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survival calculated from that time point onward and has the
disadvantage of excluding those patients who die before the land-
mark from the analysis. This proportion, however, is around 1%
according to DASISION and ENESTnd data [21,24]. Nevertheless, the
landmark method is one of the suggested approaches to comparing
survival by response category [33]. Third, as in a previous study [64],
we used baseline numbers of patients in responder and nonres-
ponder groups to weight pooled averages of overall survival,
assuming no censoring. As a further potential weakness, the model
does not take into account the speed of achieving the surrogate
response, its depth, or duration [68]. This might have induced
underestimation of long-term effectiveness of dasatinib and niloti-
nib, given that they are believed to be superior to imatinib in all
these respects and considering that the historical surrogate data is
all based on overall survival for patients taking imatinib. The extent
of this bias is however unquantiﬁable. Also, and for the same
reason, the model suits only those situations in which no subse-
quent TKI therapy is implemented following ﬁrst-line treatment.
In spite of these potential limitations, our predicted estimates
of overall survival were well aligned with observed survival from
the DASISION [42], ENESTnd [40,41], and IRIS [43] trials. As more
trial-based data, in particular patient-level data derived from RCTs,
on the relationship between cytogenetic and molecular response
and long-term outcomes, is collected and reported, it will be
possible to reﬁne our surrogate-to-ﬁnal outcome relationships.
Implications for Policy and Practice
In March 2012, NICE issued guidance recommending nilotinib and
standard-dose imatinib for the ﬁrst-line treatment of Phþ CML
[26]. Although the Appraisal Committee concluded that dasatinib
and nilotinib provided superior clinical beneﬁt over standard-dose
imatinib, as measured by surrogate outcomes, the cost per quality-
adjusted life-year (QALY) gained for nilotinib compared with
standard-dose imatinib was estimated to fall below NICE’s
willingness-to-pay threshold of €20,000 to €30,000/QALY, while
dasatinib was either dominated by nilotinib (i.e., dasatinib was lesseffective and more costly) or in comparison to imatinib was judged
to have a cost per QALY in excess of €200,000. Based on NICE’s
recommendation, it is estimated that about 509 new patients each
year in the United Kingdom will receive ﬁrst-line therapy with
imatinib and nilotinib [26].
The use of surrogate validation evidence in this case by NICE
has policy implications for cancer therapy beyond the manage-
ment of CML. With pressure for faster patient access to innovative
therapies, surrogate or intermediate outcomes (such as tumor
response, event-free survival) are increasingly being used as
primary outcomes in licensing trials of new cancer therapies.
Policymakers are also facing reimbursement [28,69] decisions on
these new treatments on the basis of evidence on impact on
intermediate outcomes with little or no deﬁnitive data on the
impact of therapy on overall survival. In response, health technol-
ogy assessment groups and national or regional agencies respon-
sible for drug coverage are beginning to introduce access
restrictions on the basis of surrogate outcome data [70,71]. Basi-
cally, new guidelines for technology appraisals state that it is no
longer sufﬁcient for new therapies to claim effectiveness on
surrogates accepted on the basis of the biological plausibility from
pathophysiological studies or the understanding of the disease
process. Instead, such claims need to be grounded on “validated”
surrogate outcomes, that is, outcomes that have proven associa-
tion and predictive capacity to the ﬁnal patient-relevant outcome.
Although the highest level of evidence should come from a meta-
analysis of RCTs demonstrating consistent association between
treatment effects on the surrogate outcomes and treatment effects
on the patient-relevant outcomes, the recent NICE evaluation of
ﬁrst-line therapies for chronic phase CML demonstrates not only
that evidence of surrogate outcome validation can be central to a
positive listing but also that observational-level evidence may
sufﬁce for the new drug to be included in public formularies.
Ongoing and future RCTs of TKI ﬁrst-line therapies in chronic
stage CML should continue to follow up patients to provide the
necessary data to examine the strength and consistency of the
relationship between treatment changes in CCyR and MMR and
long-term overall survival.
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